Drug Research最新文献_第2页

Drug Delivery Approaches for Buccal and Sublingual Administration. 口腔和舌下给药的给药途径。

IF 2.1

Drug Research Pub Date : 2025-09-01 Epub Date: 2025-04-22 DOI: 10.1055/a-2560-9884

Asad Ahmad, Juber Akhtar, Mohammad Ahmad, Rufaida Wasim, Mohammad Irfan Khan

{"title":"Drug Delivery Approaches for Buccal and Sublingual Administration.","authors":"Asad Ahmad, Juber Akhtar, Mohammad Ahmad, Rufaida Wasim, Mohammad Irfan Khan","doi":"10.1055/a-2560-9884","DOIUrl":"10.1055/a-2560-9884","url":null,"abstract":"Both local and systemic medication delivery benefit greatly from the sublingual and buccal modes of administration. They have shown to be a successful substitute for the conventional oral route, particularly in situations requiring a quick commencement of action. Via venous drainage to the superior vena cava, drugs can enter the systemic circulation quickly and directly. They are therefore helpful for individuals who have trouble swallowing as well as for medications that are highly cleared by the liver or degraded in the gastrointestinal system. Traditionally, medications that are delivered through the buccal and sublingual channels are made in three different dose forms: liquid (such as sprays and drops), semi-solid (such as gels), and solid (such as pills, wafers, films, and patches). Physiological variables frequently influence conventional dose forms, which might decrease the formulation's interaction with the mucosa and result in unexpected medication absorption. Many formulation development advancements have been made to enhance medication absorption and retention in the buccal and sublingual areas. The physiological factors influencing buccal and sublingual drug delivery as well as developments in nanoparticulate drug delivery techniques for sublingual and buccal administration will be the main topics of this review. It also discusses about the clinical development pipeline, which includes formulations that have been authorized and are undergoing clinical studies.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"239-250"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infecting Cancer to Cure It: The Power of Oncolytic Viruses in Gynecologic Oncology - A Narrative Review. 感染癌症以治疗癌症：溶瘤病毒在妇科肿瘤中的作用——综述。

IF 2.1

Drug Research Pub Date : 2025-09-01 Epub Date: 2025-06-10 DOI: 10.1055/a-2618-6935

Naina Kumar

{"title":"Infecting Cancer to Cure It: The Power of Oncolytic Viruses in Gynecologic Oncology - A Narrative Review.","authors":"Naina Kumar","doi":"10.1055/a-2618-6935","DOIUrl":"10.1055/a-2618-6935","url":null,"abstract":"Gynecological cancers, including ovarian, cervical, and endometrial malignancies, contribute significantly to the global cancer burden. Oncolytic virotherapy (OVT), using both double-stranded DNA viruses (such as adenovirus, vaccinia, and herpesvirus) and single-stranded RNA viruses (including positive-sense viruses like coxsackievirus and poliovirus, and negative-sense viruses like measles and Newcastle disease virus), has emerged as a promising therapeutic approach. This review aims to evaluate the current state and future prospects of OVT in treating gynecological cancers.A literature search was conducted from December 2005 to December 2024 using databases like PubMed, Scopus, and Web of Science with keywords such as \"oncolytic virotherapy,\" \"gynecological cancers,\" and specific virus types. Studies were included after assessing the efficacy, safety, mechanisms of action, and combinatorial use of OVT with other therapies. Exclusions included non-English publications, non-gynecological cancer studies, and those without relevant clinical or experimental data. This review thoroughly explores OVT's potential in gynecological cancer treatment.Oncolytic virotherapy demonstrates transformative potential for managing gynecological cancers. Whether used as monotherapy or in combination with other treatments, OVT shows promise in improving therapeutic outcomes and patient survival. However, further research is necessary to optimize its clinical application.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"261-274"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design and Optimization of Novel Pyrimidine-Morpholine Hybrids Through Computational Approaches for SRC Kinase Inhibitory Activity. 基于SRC激酶抑制活性计算方法的新型嘧啶-啉杂合体设计与优化。

IF 1.7

Drug Research Pub Date : 2025-07-01 Epub Date: 2025-04-17 DOI: 10.1055/a-2554-1119

Knolin K Thachil, V Soumya

{"title":"Design and Optimization of Novel Pyrimidine-Morpholine Hybrids Through Computational Approaches for SRC Kinase Inhibitory Activity.","authors":"Knolin K Thachil, V Soumya","doi":"10.1055/a-2554-1119","DOIUrl":"10.1055/a-2554-1119","url":null,"abstract":"Src (non receptor tyrosine kinase) plays a role in multiple pathways leading to tumor survival, proliferation and metastasis. Inhibiting Src kinase would be a therapeutic benefit in Src dependent cancers. Most of the nitrogen containing heterocyclic moieties found to possess variety of biological activities. Combination of heterocyclic nucleus to active hybrids has proven to be a successful method of approach to augment biological activities. Hence a series of pyrimidine-morpholine hybrids were designed and its shape similarity studies calculated with the standard Dasatinib using Tanimoto coefficient. Designed molecules were docked with human tyrosine kinase (PDB ID: 2SRC) using AutoDock vina. Docked poses were ranked based on their binding affinities which are then compared with a reference. The studies revealed that docking of hybrid molecules with 2SRC showed promising interactions with affordable ADMET properties. The stability of highly docked complex was analyzed by molecular simulation studies and the results confirmed the docking outcomes thereby making it as a potential SRC kinase inhibitor. Hence these novel pyrimidine hybrids can be considered as lead molecules for developing novel druggable moieties for breast cancer research.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"209-217"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting System (FAERS) Events For Gender Of Voriconazole Drugs. FDA不良事件报告系统（FAERS）对伏立康唑药物性别事件的现实药物警戒研究。

IF 1.7

Drug Research Pub Date : 2025-07-01 Epub Date: 2025-04-28 DOI: 10.1055/a-2575-1530

Qiong Xu, Hongxia Cheng, Xu Sun, Jing Zhao, Yingying Chen, Lingyu Ji, Yan Liang

{"title":"A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting System (FAERS) Events For Gender Of Voriconazole Drugs.","authors":"Qiong Xu, Hongxia Cheng, Xu Sun, Jing Zhao, Yingying Chen, Lingyu Ji, Yan Liang","doi":"10.1055/a-2575-1530","DOIUrl":"10.1055/a-2575-1530","url":null,"abstract":"To detect the gender variations in adverse events (AEs) of voriconazole, promote personalised medicine.A normalized dataset from Q1 2004 to Q4 2022 from the US Food and Drug Administration's Adverse Event Reporting System (FAERS) was analyses. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and P value were used to examine data from the FAERS database to detect risk signals and quantify the presence and extent of gender variations in voriconazole adverse events.A total of 7670 cases (female/male (2785/4885)) of adverse reactions to voriconazole were analysed, and drug interaction (ROR 1.30 (1.10,1.54)), death and sudden death (ROR 1.31 (1.06,1.61)), actinic keratosis (ROR 1.98 (1.10,3.57)) were found to be significantly more frequent in male patients than in female patients.We found that gender was a determinant in voriconazole-related AEs using FAERS. Our results require future validation due to the inherent limits of this open data source, but they also identify potential contributing elements for a customised side effect profiling.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"218-224"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Doxorubicin Sensitivity in Osteosarcoma Cancer Cells: Unveiling the Role of Resveratrol-Induced Oxidative DNA Damage. 增强阿霉素在骨肉瘤癌细胞中的敏感性：揭示白藜芦醇诱导的DNA氧化损伤的作用。

IF 1.7

Drug Research Pub Date : 2025-07-01 Epub Date: 2025-04-24 DOI: 10.1055/a-2567-9916

Mohammad Reza Bazavar, Hamed Helali, Linda Mohammadzadeh Boukani, Bahman Yousefi, Amir Valizadeh

引用次数: 0

Protective Effects of Niclosamide Ethanolamine Against Testosterone-Induced Benign Prostatic Hyperplasia in Rats. 氯硝胺乙醇胺对睾酮诱导的大鼠良性前列腺增生的保护作用。

IF 1.7

Drug Research Pub Date : 2025-07-01 Epub Date: 2025-04-28 DOI: 10.1055/a-2576-4153

Ali Hussein Jasim, Ahmed Rahmah Abu-Raghif, Zeena Ayad Hussein

{"title":"Protective Effects of Niclosamide Ethanolamine Against Testosterone-Induced Benign Prostatic Hyperplasia in Rats.","authors":"Ali Hussein Jasim, Ahmed Rahmah Abu-Raghif, Zeena Ayad Hussein","doi":"10.1055/a-2576-4153","DOIUrl":"10.1055/a-2576-4153","url":null,"abstract":"Benign prostatic hyperplasia is a common urological condition in aging men. The anthelmintic agent niclosamide ethanolamide exhibits a wide range of pharmacological activities. This study aimed to evaluate the protective effect of niclosamide ethanolamide in testosterone propionate-induced benign prostatic hyperplasia in rats along with elucidating the probable mechanism of action by investigating the influence on PPAR-γ and Wnt/β-catenin. 40 male Wistar rats were divided randomly into 4 groups. The healthy (control) group, received daily oral and subcutaneous administration of the vehicle. The Induced (TP) group, received only a daily dose of testosterone propionate 3 mg/kg, SC for 28 days. The treated groups (TP+FIN) and (TP+NE), received a concomitant administration of a daily dose of testosterone propionate along with finasteride 5 mg/kg/day and niclosamide ethanolamide 50 mg/kg/day respectively through oral gavage. Animals were euthanized on day 30 of the experiment and prostate tissue samples were collected to evaluate prostate index, prostate hyperplastic markers by ELISA, and gene expression by RT-qPCR. Results revealed that niclosamide ethanolamide significantly reduced prostate index compared to the induced (TP) group (P<0.0001). The agent nearly normalized BPH markers including 5α-reductase type-2 enzyme, dihydrotestosterone, and PCNA compared to the induced (TP) group (P<0.0001). The agent reduced the tissue level of β-catenin while elevating PPAR-γ to control levels (P<0.05). The current study revealed that NE can help prevent BPH in rats by upregulating the PPAR-γ receptor and inhibiting the Wnt pathway.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"225-234"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Canagliflozin: A Comprehensive Review of Advances in Preclinical Research. 卡格列净：临床前研究进展综述。

IF 1.7

Drug Research Pub Date : 2025-07-01 Epub Date: 2025-04-28 DOI: 10.1055/a-2577-1899

Bushra Imran, Farogh Ahsan, Tarique Mahmood, Mohd Masih Uzzaman Khan, Shahzadi Bano, Syed Mehdi Hasan Zaidi, Jamal Akhtar Ansari, Aditya Singh

{"title":"Canagliflozin: A Comprehensive Review of Advances in Preclinical Research.","authors":"Bushra Imran, Farogh Ahsan, Tarique Mahmood, Mohd Masih Uzzaman Khan, Shahzadi Bano, Syed Mehdi Hasan Zaidi, Jamal Akhtar Ansari, Aditya Singh","doi":"10.1055/a-2577-1899","DOIUrl":"10.1055/a-2577-1899","url":null,"abstract":"Canagliflozin is a synthetic sodium glucose transporter inhibitor (SGLT2i). It is the latest approved class of medicine used in the treatment of type 2 diabetes mellitus. As diabetes is emerging as the most common metabolic disorder, SGLT2i has lightened up the path of treatment with additional benefits. SGLT2 is located in the proximal convoluted tubules of the nephron and is responsible for glucose reabsorption. Thus, inhibiting the SGLT2 leads to a decline in glucose concentration in the plasma. The secondary effects of canagliflozin, such as cardiac protection, renoprotective, and decreased obesity, have made it more putative in the treatment of diabetes mellitus. There are some side effects of canagliflozin, such as volume depletion, genital and urinary tract infection, and lower limb amputation, which could be a matter of concern for patients. Being an anti-diabetic drug, canagliflozin also possesses anti-inflammatory and anti-cancer properties. Several studies have been conducted to determine the efficacy of canagliflozin as an anti-cancer agent. Its pharmacokinetics indicate rapid absorption, reaching peak plasma concentrations within 1-2 hours. With a half-life of approximately 12 hours, it undergoes minimal hepatic metabolism and is primarily excreted unchanged via urine. Common adverse drug reactions (ADRs) include urinary tract infections and dehydration. Clinical trials on canagliflozin, both alone and in combination with other diabetes complications, have been conducted, with some completed and others in various phases. This review article contains information about the pharmacokinetics, drug safety, and efficacy profile of canagliflozin, along with details regarding toxicological studies of canagliflozin.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"183-201"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Vitamin B6 on the Expression and Development of Tolerance to Morphine Stimulating Effects on Locomotor Activity in Mice. 维生素B6对吗啡刺激小鼠运动活性耐受表达和发展的影响。

IF 1.7

Drug Research Pub Date : 2025-06-01 Epub Date: 2025-03-05 DOI: 10.1055/a-2535-8528

Amir Abbas Barzegari, Maryam Azaddar, Mohammad-Reza Ghiasi, Hassan Sheikhi

{"title":"Effects of Vitamin B6 on the Expression and Development of Tolerance to Morphine Stimulating Effects on Locomotor Activity in Mice.","authors":"Amir Abbas Barzegari, Maryam Azaddar, Mohammad-Reza Ghiasi, Hassan Sheikhi","doi":"10.1055/a-2535-8528","DOIUrl":"10.1055/a-2535-8528","url":null,"abstract":"Chronic use of morphine may induce tolerance to its different pharmacological effects. Vitamin B6 has a central role, as a cofactor, in the biosynthesis of neurotransmitters that are involve in morphine's effects. Moreover, this vitamin affects on morphine's reward and analgesic properties. Therefore, the current research aimed to evaluate the effects of vitamin B6 on the expression and acquisition of tolerance to morphine locomotor-stimulating effects.Twenty groups of mice (n=8) were selected randomly. Acute effects of different doses of morphine (1-30 mg/kg) or vitamin B6 (25-75 mg/kg) on locomotor activity were evaluated using an activity meter. Induction of tolerance was conducted using morphine (30 mg/kg)×2 times a day×3 days plus a single dose of morphine (30 mg/kg) on fourth day. In expression experiment, vitamin B6 (25-75 mg/kg) or saline was injected one hour before the last dose morphine, after tolerance induction. In the acquisition test, one hour before each dose of morphine (in the first three days of tolerance induction) saline or vitamin B6 (25-75 mg/kg) was administered to mice.Although vitamin B6 had no effect on locomotion, administration of morphine had a biphasic effect on mice's locomotor activity; it decreased locomotion at a low dose (5 mg/kg) and increased it at a high dose (30 mg/kg). Furthermore, administration of vitamin B6 before morphine could inhibit the expression and the acquisition of tolerance to morphine-stimulating effects on locomotor activity.Vitamin B6 may be considered as a nutritional supplement in reducing morphine tolerance.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"140-147"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Possible Drug-Drug Interactions Between Mesalamine and Tricyclic Antidepressants Through CYP2D6 Metabolism - In silico and In vitro Analyses. 美沙拉明和三环抗抑郁药通过CYP2D6代谢可能的药物相互作用-计算机和体外分析。

IF 1.7

Drug Research Pub Date : 2025-06-01 Epub Date: 2025-04-01 DOI: 10.1055/a-2551-2418

Melek B Ozen, Isil Gazioglu, Ozden Ozgun Acar, Huseyin Guner, Gurkan Semiz, Alaattin Sen

{"title":"Possible Drug-Drug Interactions Between Mesalamine and Tricyclic Antidepressants Through CYP2D6 Metabolism - In silico and In vitro Analyses.","authors":"Melek B Ozen, Isil Gazioglu, Ozden Ozgun Acar, Huseyin Guner, Gurkan Semiz, Alaattin Sen","doi":"10.1055/a-2551-2418","DOIUrl":"10.1055/a-2551-2418","url":null,"abstract":"Mesalamine (mesalazine, 5-aminosalicylic acid, 5-ASA) is an essential anti-inflammatory agent both used for therapy and as a remission control in patients with inflammatory bowel diseases (IBD) such as ulcerative colitis (UC). Tricyclic antidepressants (TCAs) are used to alleviate remaining symptoms in patients already receiving IBD therapy or with quiescent inflammation. The cytochrome P4502D6 enzyme is involved in the metabolism of TCAs. Hence, it is crucial to investigate the role of CYP2D6 in 5-ASA metabolism. Initially, in silico analysis involving the docking of 5-ASA to CYP2D6 and molecular dynamics simulations was conducted. Next, the rate of O-demethylation of a nonfluorescent probe 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) into a fluorescent metabolite AMHC (3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-hydroxy-4-methylcoumarin) was optimized with baculosomes co-expressing human CYP2D6 and human P450 oxidoreductase (hCPR) to monitor CYP2D6 activity in a microtiter plate assay. The apparent Km and Vmax were found to be 1.30 μM and 32.68 pmol/min/mg of protein for the O-demethylation of AMMC to AMHC, and the reaction was linear for 40 min. Then, nonselective inhibition of CYP2D6 activity with various concentrations of 5-ASA was detected. Finally, the conversion of AMMC to metabolites was analyzed by HPLC-ESI-MS/MS spectrometry, and none were identified. Thus, this study suggests that concurrent use of mesalamine with TCA may lead to adverse effects, and CYP2D6 genotyping should be routinely performed on these patients to eliminate possible threats.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"169-178"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Randomized, Controlled Study Evaluating Effects of Saccharomyces boulardii in Adult Patients with Asthma. 一项评价博氏酵母菌对成年哮喘患者疗效的随机对照研究。

IF 1.7

Drug Research Pub Date : 2025-06-01 Epub Date: 2025-04-14 DOI: 10.1055/a-2564-2569

Kavosh Ansari Dezfouli, Mahboubeh Darban, Maral Hemmati, Mazyar Zahir, Mojtaba Soltani Kermanshahi, Anna Abdolshahi, Hani Sadr, Bahador Bagheri

{"title":"A Randomized, Controlled Study Evaluating Effects of Saccharomyces boulardii in Adult Patients with Asthma.","authors":"Kavosh Ansari Dezfouli, Mahboubeh Darban, Maral Hemmati, Mazyar Zahir, Mojtaba Soltani Kermanshahi, Anna Abdolshahi, Hani Sadr, Bahador Bagheri","doi":"10.1055/a-2564-2569","DOIUrl":"10.1055/a-2564-2569","url":null,"abstract":"To determine the potential benefit of adding Saccharomyces boulardii (S. boulardii) probiotic supplementation to conventional treatments in asthmatic patients.In this randomized, double-blinded, and placebo-controlled trial 50 asthmatic patients were enrolled. The eligible subjects received either S. boulardii (N=25) or placebo (N=25) added to conventional treatments for three months. Spirometry parameters (FEV1, FVC, FEV1/FVC, and FEF 25-75%) and blood test parameters (CBC, eosinophil percentage, IgE, IL-5, ESR and CRP) were measured and compared at baseline and after treatment completion.The mean age was 39.22±12.55 years. As compared to baseline values, a significant improvement was noted in FEV1 in patients who received S. boulardii (p=0.026). Although the changes in FEV1, FVC, FEV1/FVC, and FEF 25-75% were comparable between the study groups, the differences were not statistically significant (p ˃ 0.05). In addition, patients who received probiotic showed lower levels of IL-5 and IgE in comparison with patients who received placebo.Our findings showed that the addition of S. boulardii to conventional treatments partially improved the pulmonary function and was associated with reductions in IgE and IL-5 levels.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"162-168"},"PeriodicalIF":1.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0